Preliminary new blood test to detect Alzheimer's disease uncovered

February 11, 2011

UT Southwestern Medical Center scientists have helped develop a novel technology to diagnose Alzheimer's disease from blood samples long before symptoms appear.

This preliminary technology, which uses synthetic molecules to seek out and identify disease-specific antibodies, also could be used eventually in the development of specific for a range of other hard-to-diagnose diseases and conditions, including Parkinson's disease and immune system-related diseases like and , the researchers predict.

"One of the great challenges in treating patients with is that once symptoms appear, it's too late. You can't un-ring the bell," said Dr. Dwight German, professor of and an author of the paper published in the Jan. 7 edition of Cell. "If we can find a way to detect the disease in its earliest stages – before cognitive impairment begins – we might be able to stop it in its tracks by developing new treatment strategies."

Because patients with Alzheimer's disease (AD) exhibit immune system activation and neurodegeneration in several brain regions, researchers in the study hypothesized that there may be numerous antibodies in the serum of affected patients that are specific to the disease and can serve as a biomarker.

Antigens – substances such as protein from a virus or bacteria that triggers an immune response – traditionally have been necessary for the discovery of antibody biomarkers. It has been impossible previously to identify an antibody (a type of targeted immune molecule) without first knowing the antigen that triggers its production.

The new study, however, challenges conventional wisdom and uses synthetic molecules (peptoids) rather than antigens to successfully detect signs of disease in patients' . These peptoids have many advantages; they can be modified easily and can be produced quickly in relatively large amounts at lower cost.

The adaptive immune system is thought to be a rich source of protein biomarkers, but diagnostically useful antibodies remain undiscovered for a large number of diseases, Dr. German said. This is, in part, because the antigens that trigger an immune response in many diseases are unknown. The technology behind this discovery is essentially an reader, which is designed to pick out antibodies without knowing in advance which ones to look for.

The researchers used a combination library of several thousand peptoids to screen serum samples from mice with multiple sclerosis-like symptoms as well as from healthy control mice. The particular peptoids that retained more antibodies from the blood samples of the diseased animals were identified as potential agents for capturing diagnostically useful molecules.

The investigators then examined serum samples from six AD patients, six healthy patients and six patients with Parkinson's. Three peptoids were identified that captured six times the IgG antibody levels in all of the Alzheimer's patients when compared to the control group or to the Parkinson's patients. Two of the peptoids were found to bind the same IgG antibody, while the third was shown to bind to different – meaning there are at least two candidate biomarkers for AD. Using an additional set of 16 normal control subjects and 10 subjects at the very early state of AD, the three candidate biomarkers identified AD with 90 percent accuracy.

"The results of this study, though preliminary, show great potential for becoming a landmark," said Dr. German.

Related Stories

Recommended for you

Engineered protein treatment found to reduce obesity in mice, rats and primates

October 19, 2017
(Medical Xpress)—A team of researchers with pharmaceutical company Amgen Inc. report that an engineered version of a protein naturally found in the body caused test mice, rats and cynomolgus monkeys to lose weight. In their ...

New procedure enables cultivation of human brain sections in the petri dish

October 19, 2017
Researchers at the University of Tübingen have become the first to keep human brain tissue alive outside the body for several weeks. The researchers, headed by Dr. Niklas Schwarz, Dr. Henner Koch and Dr. Thomas Wuttke at ...

Cancer drug found to offer promising results in treating sepsis in test mice

October 19, 2017
(Medical Xpress)—A combined team of researchers from China and the U.S. has found that a drug commonly used to treat lung cancer in humans offers a degree of protection against sepsis in test mice. In their paper published ...

Tracing cell death pathway points to drug targets for brain damage, kidney injury, asthma

October 19, 2017
University of Pittsburgh scientists are unlocking the complexities of a recently discovered cell death process that plays a key role in health and disease, and new findings link their discovery to asthma, kidney injury and ...

Study reveals key molecular link in major cell growth pathway

October 19, 2017
A team of scientists led by Whitehead Institute has uncovered a surprising molecular link that connects how cells regulate growth with how they sense and make available the nutrients required for growth. Their work, which ...

Inflammation trains the skin to heal faster

October 18, 2017
Scars may fade, but the skin remembers. New research from The Rockefeller University reveals that wounds or other harmful, inflammation-provoking experiences impart long-lasting memories to stem cells residing in the skin, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.